ESTRO 2023 - Abstract Book

S491

Sunday 14 May 2023

ESTRO 2023

In total, 168 (84 in each arm) patients were randomized in the Dutch trial and 150 (75 in each arm) were randomized in the Spanish trial (Table 1). Median follow up was 41.7 (95%CI 35.7-47.6) months. In total, 202 of 318 patients died (104 in PCI, 98 in HA-PCI), 61 (19.2%) developed BM (30 in PCI, 31 in HA-PCI). The BM was single in 15 patients (7 in PCI, 8 in HA PCI, p=0.8). Nine of the 61 patients had BM within HA area (4 in PCI, 5 in HA-PCI, p=1.0). One had single BM within HA area (HA arm, p=1.0) Overall, 47 out of 953 (4.9%) SRCF assessments were out of the time window. The compliance rate within the time window dropped from 97.5% at baseline to 64.7% at 24-months, the cognitive impairment incidence ranged from 25.6% to 53.8% (Figure 1), which were not statistically significant between arms. Six patients did not assessed SRCF and 147 of 312 (47.1%) patients experienced cognitive impairment at least once (78 in PCI, 69 in HA-PCI, p=0.3). GEE analysis showed that HA-PCI did not have a significant impact on SCRF ( β = 1.7, p=0.4) nor cognitive impairment (SRCF<75) (OR 0.8, 95%CI 0.6 – 1.2, p = 0.3).